In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
All Keywords
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, adolescents, delta variant, Israel, vaccine effectiveness, 【초록키워드】 Vaccine, BNT162b2 vaccine, coronavirus, Infection, Delta, B.1.617.2, severe acute respiratory syndrome Coronavirus, BNT162b2, outbreak, Effectiveness, respiratory, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, effective, evaluated, approved, the vaccine, 【제목키워드】 Delta, Adolescent, of BNT162b2,
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, adolescents, delta variant, Israel, vaccine effectiveness, 【초록키워드】 Vaccine, BNT162b2 vaccine, coronavirus, Infection, Delta, B.1.617.2, severe acute respiratory syndrome Coronavirus, BNT162b2, outbreak, Effectiveness, respiratory, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, effective, evaluated, approved, the vaccine, 【제목키워드】 Delta, Adolescent, of BNT162b2,
이스라엘에서 중증 급성 호흡기 증후군 코로나바이러스 2에 대한 BNT162b2 백신은 B.1.617.2(델타) 변종 우성 감염이 발생하기 직전인 2021년 6월에 청소년에게 사용하도록 승인되었습니다. 우리는 단기 백신 효과를 평가했고 이 환경에서 이 인구 집단에서 백신이 매우 효과적이라는 것을 발견했습니다.